Contract Manufacturing Organization (CDMO/CMO) Selection Guide for Pharma

The buyer problem

Manufacturing capacity at a qualified CDMO is scarce, especially for biologics, and a bad selection shows up months later as a failed inspection, a blown technology-transfer timeline, or a batch that never gets released. Sponsors need a way to separate genuine, site-specific GMP track record and in-use capacity from a slide deck of theoretical capabilities.

What a contract manufacturing organization (cdmo/cmo) selection guide for pharma vendor does

A CDMO develops and validates the manufacturing process for a drug substance or drug product, then manufactures it under current Good Manufacturing Practice (cGMP) conditions, handling everything from process development and analytical method validation through scale-up, technology transfer, and commercial-scale production. A CMO typically performs only the manufacturing step, using a process the sponsor has already developed and handed over. Both may also handle fill-finish, packaging, and clinical or commercial supply logistics.

Methods and techniques

• Process development and formulation
• Analytical method development and validation
• cGMP drug substance manufacturing
• cGMP drug product / fill-finish manufacturing
• Scale-up and technology transfer
• Clinical trial and commercial packaging

What to verify before you retain

• GMP inspection history. Request the facility's most recent FDA Form 483 observations and EU GMP inspection outcomes for the specific site that will run your batch, not just the parent company's overall record.
• Modality-specific capacity. Confirm the CDMO has demonstrated, in-use capacity (not just announced capacity) for your specific modality, whether small molecule, monoclonal antibody, ADC, cell/gene therapy, or mRNA.
• Technology transfer track record. Ask for references on tech-transfer timelines from a comparable process, and what documentation package they require from you at handoff.
• Supply chain and single-source risk. Identify any single-source raw materials or components the CDMO depends on, and their contingency plan for a supply disruption.
• Batch scheduling and slot availability. Confirm real slot availability against your timeline; capacity at large CDMOs is frequently booked 12-18+ months out.
• Quality agreement and change control. Review the proposed quality agreement and change-control process before committing, since it governs how process changes are documented and approved.

Questions to put in your RFP

1. What is your facility's most recent FDA and/or EU GMP inspection outcome, and were there any Form 483 observations?
2. What is your current, in-use manufacturing capacity for our specific modality, and what is your actual slot availability against our timeline?
3. Walk us through your technology transfer process and typical timeline from a comparable process.
4. What raw materials or components are single-sourced, and what is your contingency plan for a supply disruption?
5. What does your standard quality agreement and change-control process look like?
6. Can you provide references from at least two sponsors who ran a comparable program with you in the last two years?

Red flags

• Unwilling to disclose recent inspection findings for the specific manufacturing site proposed.
• Vague about actual available capacity versus theoretical or announced capacity.
• No named technical lead or quality contact before contract signature.
• Resistance to a standard quality agreement or change-control process.
• Cannot provide sponsor references for a comparable modality and scale.

Standards and governing bodies

Bodies referenced in this category. Listed for context; they do not endorse this index or any vendor. Verify any credential directly with the issuing body.

FDA

U.S. Food and Drug Administration. Inspects drug manufacturing facilities for compliance with Current Good Manufacturing Practice (cGMP) regulations under 21 CFR Parts 210 and 211.

EU GMP

European Medicines Agency GMP framework. Coordinates GMP inspections of manufacturing sites supplying the EU market under EudraLex Volume 4.

ICH Q7

International Council for Harmonisation Q7. The internationally harmonized GMP guideline specifically for active pharmaceutical ingredient (API) manufacturing.